,

Use of cannabinol in the treatment of epilepsy: Lennox-Gastaut Syndrome , Dravet, and Tuberous Sclerosis Complex

Authors

Antonio Silvinato, Idevaldo Floriano, Wanderley Marques Bernardo

Published

January 30, 2023

Abstract

Purpose: The objective of this systematic review with meta-analysis was to evaluate the efficiency, safety and short and long term tolerability of Cannabidiol CBD, as an adjunct treatment , in children and adults with Dravet Syndrome (SD) and Lennox Gastaut Syndrome(LGS) or Tuberous Sclerosis Complex with inadequate control of seizures.

 
 

Full Paper>>

Citations

Silvinato, A., Floriano, I., & Bernardo, W. M. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet and Tuberous Sclerosis Complex.

/by
You might also like
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.
Real-World evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex
The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex
Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.